title: Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation.
abstract: Chronic bilateral subthalamic stimulation leads to a spectacular clinical improvement in patients with motor complications. However, the post-operative body weight gain involved may limit the benefits of surgery and induce critical metabolic disorders. Twenty-four Parkinsonians (61.1 +/- 1.4 years) were examined 1 month before (M - 1) and 3 months after (M + 3) surgery. Body composition and energy expenditure (EE) were measured (1) over 36 h in calorimetric chambers (CC) with rigorous control of food intakes and activities [sleep metabolic rate, resting activities, meals, 3 or 4 sessions of 20 min on a training bicycle at 13 km/h and daily EE] and (2) in resting conditions (basal metabolic rate) during an acute L-dopa challenge (M - 1) or according to acute 'off' and 'on' stimulation (M + 3). Before surgery, EE was compared between the Parkinsonian patients and healthy subjects matched for height and body composition (metabolic rate during sleep, daily EE) or matched to predicted values (basal metabolic rate). Before surgery, in Parkinsonian men but not women, (1) daily EE was higher while sleep metabolic rate was lower compared to healthy matched men (+9.2 +/- 3.9 and -8.2 +/- 2.3%, respectively, P < 0.05) and (2) basal metabolic rate (L-dopa 'on') was higher than predicted basal metabolic rate (+11.5 +/- 4.0%, P < 0.05) but was further increased without L-dopa (+8.4 +/- 3.2% vs L-dopa 'on', P < 0.05). EE during daily activities was higher during 'off' periods compared to 'on' periods for both men (+19.3 +/- 3.3%, P < 0.0001) and women (+16.1 +/- 4.7%, P < 0.01). After surgery, there was a 3.4 +/- 0.6 kg (P < 0.0001) body weight increase together with fat mass (P < 0.0001) and fat-free mass (P < 0.05) in Parkinsonian men and a 2.6 +/- 0.8 kg (P < 0.05) body weight increase together with fat mass (P < 0.05) in Parkinsonian women. Sleep metabolic rate increased in men (+7.5 +/- 2.0%, P < 0.01) to reach control values but remained unchanged in women. Daily EE decreased significantly in both men and women (-7.3 +/- 2.2% and -13.1 +/- 1.7%, respectively, P < 0.01) but there was no correlation between daily EE changes and body weight gain. Parkinson's disease is associated with profound alterations in the central control of energy metabolism. Normalization of energy metabolism after DBS-STN implantation may favour body weight gain, of which quality was gender specific. As men gained primarily fat-free mass, a reasonable weight gain may be tolerated, in contrast with women who gained only fat. Other factors such as changes in free-living physical activity may help to limit body weight gain in some patients.
authors.affiliation: INRA, Centre Clermont-Ferrand-Theix, UMR 1019, Unité de Nutrition Humaine, CRNH Auvergne, Clermont-Ferrand, F-63009 France.
authors.forename: C
authors.initials: C
authors.lastname: Montaurier
authors.forename: B
authors.initials: B
authors.lastname: Morio
authors.forename: S
authors.initials: S
authors.lastname: Bannier
authors.forename: P
authors.initials: P
authors.lastname: Derost
authors.forename: P
authors.initials: P
authors.lastname: Arnaud
authors.forename: M
authors.initials: M
authors.lastname: Brandolini-Bunlon
authors.forename: C
authors.initials: C
authors.lastname: Giraudet
authors.forename: Y
authors.initials: Y
authors.lastname: Boirie
authors.forename: F
authors.initials: F
authors.lastname: Durif
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D001481:Basal Metabolism; D001823:Body Composition; D002153:Calorimetry, Indirect / Q000379:methods; D046690:Deep Brain Stimulation; D004435:Eating; D004567:Electrodes, Implanted; D002149:Energy Intake; D004734:Energy Metabolism; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D011446:Prospective Studies; D013238:Stereotaxic Techniques; D020531:Subthalamic Nucleus / Q000503:physiopathology*; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa